Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
ruxolitinib janus kinase 1 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 2.33 approved inhibitor
ruxolitinib janus kinase 1 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 2.33 approved unknown
ruxolitinib tyrosine-protein kinase jak1 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 2.33 approved inhibitor
ruxolitinib janus kinase 1 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 2.33 approved unknown
ruxolitinib tyrosine-protein kinase jak1 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 2.33 approved inhibitor
ruxolitinib janus kinase 1 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 2.33 approved inhibitor
ruxolitinib janus kinase 2 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 4.01 approved inhibitor
ruxolitinib tyrosine-protein kinase jak2 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 4.01 approved inhibitor
ruxolitinib janus kinase 2 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 4.01 approved unknown
ruxolitinib janus kinase 2 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 4.01 approved unknown
ruxolitinib janus kinase 2 NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 4.01 approved inhibitor
ruxolitinib tyrosine-protein kinase jak2 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 4.01 approved inhibitor
ruxolitinib tyrosine-protein kinase jak3 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 0.61 approved inhibitor
ruxolitinib tyrosine-protein kinase jak3 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 0.61 approved inhibitor
ruxolitinib urokinase plasminogen activator surface receptor NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 2.12 approved unknown
ruxolitinib urokinase plasminogen activator surface receptor NA Successful target TTD , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 2.12 approved unknown
ruxolitinib non-receptor tyrosine-protein kinase tyk2 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 0.21 approved inhibitor
ruxolitinib non-receptor tyrosine-protein kinase tyk2 small molecule NA drugbank , DGIDB Eczema[MeSHID:D004485]
Disease[MeSHID:D004194]
Splenomegaly[MeSHID:D013163]
Graft-vs-Host Disease[MeSHID:D006086]
Immunocompetence[MeSHID:D007121]
Primary Myelofibrosis[MeSHID:D055728]
Polycythemia Vera[MeSHID:D011087]
Thrombocythemia
Essential[MeSHID:D013920]
Dermatitis
Atopic[MeSHID:D003876]
Prescription procedure[MeSHID:D055656]
Term Birth[MeSHID:D047929]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of pancreas[MeSHID:D010190]
Pancreatic carcinoma[MeSHID:C562463]
Vitiligo[MeSHID:D014820]		 0.21 approved inhibitor
click here to return to the previous page